Loading provider…
Loading provider…
Hematology & Oncology Physician in Maywood, IL
NPI: 1558348433Primary Practice Location
Loyola University Medical Center
2160 S 1st Ave, IL
Primary Employer
Loyola University Medical Center
loyola.com
HQ Phone
Get MD Patrick's Phone Numberphone_androidMobile
Get MD Patrick's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardIL State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 31 | 233 |
| 2 | 99239Hospital discharge day management, more than 30 minutes | 23 | 28 |
| 3 | 99223Initial hospital inpatient care, typically 70 minutes per day | 22 | 30 |
| 4 | 99214Established patient office or other outpatient visit, 30-39 minutes | 19 | 42 |
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Authors: Sattva Neelapu, Ian Flinn, David Miklos, Peter Mcsweeney, Tanya Siddiqi, John Timmerman, Nancy Bartlett, Frederick Locke, Armin Ghobadi, Lazaros Lekakis, Abhinav Deol, Andre Goy, Caron Jacobson, Umar Farooq, Ira Braunschweig, Alex Herrera
Publication Date: 2023-05
Authors: Mark Schroeder, Ivana Micallef, Muzaffar Qazilbash, Denise Pereira, Zachary Crees, Tahir Latif, John Dipersio, John Hiemenz
Journal: Nat Med
Publication Date: 2023-04-17
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.
Authors: Armin Ghobadi, Gary Schiller, John Rossi, William Wierda, Ryan Cassaday
Publication Date: 2021-04-29
Lead Sponsor: Genzyme, a Sanofi Company
Intervention / Treatment: DRUG: Placebo, DRUG: granulocyte colony-stimulating factor (G-CSF), DRUG: plerixafor